Altis Labs Raises $25M Series A

Altis Labs, a Toronto-based AI endpoint company, has secured $25 million in Series A funding to accelerate clinical trial development. The company specializes in using AI models trained on real-world outcomes to predict patient survival and clinical benefit in oncology trials more accurately than traditional imaging endpoints.

Investors

The funding round was co-led by OrbiMed and Qiming Venture Partners USA. Additional participants included Innovation Endeavors, Benchstrength, Fusion Fund, and Lumira Ventures via the Cancer Breakthrough Fund.

Altis Labs Use of Funds

The company plans to use the capital to expand its AI models across additional cancer types, scale commercial deployment with global biopharmaceutical partners, and establish its AI endpoints as a new standard for oncology clinical trials.

About Altis Labs

Founded by Felix Baldauf-Lenschen, Altis Labs develops AI endpoints designed to help accelerate clinical trials and improve the measurement of treatment efficacy. Their flagship product, IPRO, automatically generates survival predictions from routine radiology scans, helping pharmaceutical companies analyze clinical trial data more reliably.

Funding Details

Company Website: https://altislabs.com

Company: Altis Labs
Raised: $25M
Round: Series A
Funding Date: September 2026
Lead Investor: OrbiMed, Qiming Venture Partners USA
Additional Investors: Innovation Endeavors, Benchstrength, Fusion Fund, Lumira Ventures
Company Website: www.altislabs.com
Software Category: Healthcare AI
Source: https://www.axios.com/pro/biotech-deals/2026/09/17/altis-labs-series-a-ai-clinical-trial